Abou-Khalil S, Abou-Khalil W H, Yunis A A
Biochem Pharmacol. 1986 Jun 1;35(11):1855-9. doi: 10.1016/0006-2952(86)90303-5.
It was shown recently that the antiaggregating agent ticlopidine and some of its analogues inhibit the energy-conserving mechanism in mitochondria [Abou-Khalil et al., Biochem. Pharmac. 33, 3893 (1984)]. In the present investigation, the mechanism of inhibition by these drugs was investigated by studying their effects on key reactions of oxidative phosphorylation. Liver mitochondria were isolated from Sprague-Dawley male rats, and the interactions of ticlopidine and six of its analogues with those key reactions were tested. We found: The transport of phosphate, glutamate and succinate into mitochondria was not affected significantly by ticlopidine or any of its analogues; however, it was inhibited by both mersalyl and N-ethylmaleimide as expected. There was no inhibitory effect of the tested drugs on the mitochondrial [3H]ADP translocation activity; rather, ticlopidine produced a concentration-dependent increase of that activity, reaching 54% with 20 micrograms/ml. Ticlopidine and its analogue, PCR 5325, increased the latent ATPase activity by about 400% and the DNP-dependent ATPase by about 50%. Also, PCR 4099 caused a 115% increase in the latent activity, whereas the effects of the remaining analogues varied from slight activation to slight inhibition. Under nonphosphorylation conditions, the mitochondrial H+ extrusion resulting from succinate oxidation was inhibited by ticlopidine in a concentration-dependent manner reaching a quasi total inhibition with 40 micrograms/ml. While PCR 5325 gave results similar to ticlopidine, PCR 4099 was less inhibitory and the other analogues were ineffective. These data indicate that the inhibitory action caused by ticlopidine and some of its analogues on oxidative phosphorylation does not reside at one particular site in the mitochondrial membrane; rather, the inhibition seems to be the outcome of profound alterations in mitochondrial ADP translocase, latent ATPase, and proton translocation in the respiratory chain.
最近研究表明,抗聚集剂噻氯匹定及其一些类似物可抑制线粒体中的能量保存机制[阿布-哈利勒等人,《生物化学与药理学》33, 3893 (1984)]。在本研究中,通过研究这些药物对氧化磷酸化关键反应的影响来探究其抑制机制。从斯普拉格-道利雄性大鼠中分离出肝脏线粒体,并测试了噻氯匹定及其六种类似物与这些关键反应的相互作用。我们发现:噻氯匹定或其任何一种类似物对磷酸盐、谷氨酸盐和琥珀酸盐进入线粒体的转运没有显著影响;然而,正如预期的那样,汞撒利和N-乙基马来酰亚胺均能抑制这种转运。所测试的药物对线粒体[3H]ADP转位活性没有抑制作用;相反,噻氯匹定使该活性呈浓度依赖性增加,在20微克/毫升时达到54%。噻氯匹定及其类似物PCR 5325使潜在ATP酶活性增加约400%,使DNP依赖性ATP酶增加约50%。此外,PCR 4099使潜在活性增加115%,而其余类似物的作用则从轻微激活到轻微抑制不等。在非磷酸化条件下,噻氯匹定以浓度依赖性方式抑制由琥珀酸氧化引起的线粒体H+ 外流,在40微克/毫升时达到几乎完全抑制。虽然PCR 5325的结果与噻氯匹定相似,但PCR 4099的抑制作用较小,其他类似物则无效。这些数据表明,噻氯匹定及其一些类似物对氧化磷酸化的抑制作用并不存在于线粒体膜的一个特定部位;相反,这种抑制似乎是线粒体ADP转位酶、潜在ATP酶和呼吸链中质子转运发生深刻改变的结果。